Pharma Journalist -

Catalent welcomed the news that DiaMedica Therapeutics has received U.S. Food and Drug Administration (FDA) approval to commence Phase 2 clinical trials of its lead candidate, DM199,…
Read More...

Roche announced positive topline results from the pivotal Part 2 of the FIREFISH study, evaluating risdiplam in infants aged 1-7 months with Type 1 spinal muscular atrophy (SMA). The…
Read More...

Epizyme, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of TAZVERIK (tazemetostat) for the treatment of adults and pediatric patients…
Read More...

INHIBITOR Therapeutics, Inc. a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to inhibit progression of cancerous and…
Read More...

SMi Reports: Alexander D. Graham’s interview released for SMi’s 3D Cell Culture Conference, taking place in February 2020 in London. In just under 4 weeks SMi’s 4th Annual 3D Cell…
Read More...

Roche announced that the European Commission has granted conditional marketing authorisation for Polivy (polatuzumab vedotin), in combination with bendamustine plus MabThera (rituximab)…
Read More...

Bellicum Pharmaceuticals announced it has entered into an asset purchase agreement under which The University of Texas MD Anderson Cancer Center will acquire Bellicum’s approximately…
Read More...

Calidi Biotherapeutics, Inc., a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, announced Series A investments from two…
Read More...

Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS), a US subsidiary of Hitachi Chemical Co., Ltd. that engages in contract manufacturing and manufacturing development of cell…
Read More...

Horizon Therapeutics plc announced that the U.S. Food and Drug Administration (FDA) has approved TEPEZZATM (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED). TEPEZZA is…
Read More...